Since 2014, Sen-Jam has been driven to revolutionize pain management - to usher in a new dawn for all of full strength living
Sen-Jam has been working hard amassing 24 both domestic and international patents and patents pending
-
April
Listed on RedCrow’s Equity CrowdFunding site
-
April
Sen-Jam featured in StartUp Healths Insights
-
March
Alcohol Hangover Paper Published featuring SJP-001
-
March
Off-Label use of our Opioid Withdrawal Product used in tapering Suboxone
-
January
Sen-Jam participates in StartUp Health Festival during JP Morgan Health Conference2020
-
Fall
Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder
-
November
Presented at Life Science Summit, NYC
-
Fall
Patent issued for SJP-001
-
September
Led panel discussion for Opioid Crisis Working Group -
August
Highlighted in Real Leaders Magazine for work related to opioid withdrawal -
July
Op Ed published in StartUp Health Magazine
-
June
Partnered with Stony Brook University - Center for Biotechnology
-
Spring
Conducted additional pre-clinical studies for opioid withdrawal (SJP-005)
-
January
Sen-Jam participates in StartUp Health Festival, the premier forum of Health Transformers during JP Morgan Health Conference
2019
-
Fall
Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder
-
June
Sen-Jam attends Research Society on Alcoholism Conference
-
May
Sen-Jam attends BioTech event at Cold Spring Harbor Labs
-
Spring
Spring pre-clinical studies for opioid withdrawal (SJP-005)
-
March
Sen-Jam files patent for treatment of enteropathic arthritis (SJP-004)
-
January
Sen-Jam attends JP Morgan Health Conference
2018
-
November
Sen-Jam Wins RESI Innovation Challenge
-
October
Sen-Jam first Corporate Retreat
-
September
Sen-Jam files patents to inhibit symptoms associated with opioid withdrawal (SJP-005), opioid dependence (SJP-006), and opioid tolerance (SJP-007)
-
August
Sen-Jam files patent to inhibit adverse effects associated with vaccinations (SJP-003)
-
August
Sen-Jam Pharmaceutical LLC is formed
-
July
Sen-Jam attends Research Society on Alcoholism Conference
-
June
Investigational New Drug (IND) application opened with the FDA to begin Phase I Clinical Trial
-
June
Sen-Jam files patent to inhibit symptoms associated with Viral Respiratory Infections (SJP-002)
-
April
Sen-Jam presents in Amsterdam at 9th annual Alcohol Hangover Research Group Conference
2017
-
October
Sen-Jam completes Pre-Investigational new drug meeting with FDA
-
August
Trademarks filed & Scientific Advisory Board established
-
June
Sen-Jam presents findings to Alcohol Hangover Research Group at National Institute on Alcohol Abuse and Alcoholism Conference
-
March
Conducted IRB Study for Prevention of Alcohol Hangover (SJP-001)
2016
-
March
Provisional Patents Filed
2015
-
Fall
Volunteer Study Begins—SJP-001
-
Spring
Jackie Iversen has Eureka moment
2014